The Cooper Companies, Inc. (NASDAQ:COO – Get Free Report) has received a consensus recommendation of “Hold” from the nineteen ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $68.60.
A number of analysts have weighed in on COO shares. Stifel Nicolaus set a $70.00 price target on Cooper Companies and gave the stock a “buy” rating in a report on Thursday, September 10th. Barclays raised Cooper Companies to a “hold” rating in a research note on Wednesday, October 7th. Mizuho set a $75.00 target price on Cooper Companies and gave the company an “outperform” rating in a research report on Thursday, September 10th. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, UBS Group decreased their target price on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research note on Thursday, September 10th.
View Our Latest Stock Analysis on Cooper Companies
Insider Buying and Selling at Cooper Companies
In other Cooper Companies news, Director Lawrence Kurzius purchased 10,000 shares of the business’s stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $53.91 per share, for a total transaction of $539,100.00. Following the acquisition, the director owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. This represents a 90.10% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Walter Rosebrough, Jr. acquired 7,000 shares of Cooper Companies stock in a transaction dated Friday, September 11th. The shares were bought at an average cost of $54.11 per share, with a total value of $378,770.00. Following the transaction, the director owned 17,000 shares in the company, valued at approximately $919,870. This trade represents a 70.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Cooper Companies during the second quarter valued at about $1,077,762,000. Generation Investment Management LLP bought a new position in shares of Cooper Companies during the 2nd quarter worth about $356,304,000. Jupiter Topco LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter valued at about $305,074,000. JANA Partners Management LP grew its stake in shares of Cooper Companies by 0.5% in the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock valued at $256,900,000 after buying an additional 17,322 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Cooper Companies by 3.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock valued at $248,758,000 after buying an additional 103,044 shares during the period. 24.39% of the stock is owned by institutional investors.
Key Headlines Impacting Cooper Companies
Here are a few of the latest headlines about COO:
- Positive Sentiment: A recent article highlights Cooper’s relatively high cash yield, suggesting investors may be overlooking a potential source of value. The supplied information does not include the article’s supporting figures or analysis. Why Is Everyone Ignoring Cooper Companies Stock’s High Cash Yield?
- Negative Sentiment: Rosen Law Firm says it is investigating potential securities claims tied to allegations that Cooper may have provided materially misleading business information. The notices encourage affected investors to contact the firm; they do not establish wrongdoing or indicate that a claim has been proven. The investigation could nevertheless weigh on sentiment and raise concerns about potential legal costs or reputational impact. Rosen investigation notice Rosen investor notice
Cooper Companies Trading Up 0.7%
NASDAQ COO traded up $0.46 during mid-day trading on Friday, reaching $62.65. 1,574,266 shares of the stock were exchanged, compared to its average volume of 2,699,030. Cooper Companies has a one year low of $51.01 and a one year high of $89.83. The stock has a 50 day simple moving average of $58.49 and a 200-day simple moving average of $68.15. The stock has a market cap of $11.91 billion, a P/E ratio of 21.38, a P/E/G ratio of 2.44 and a beta of 0.83. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73.
Cooper Companies (NASDAQ:COO – Get Free Report) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. Cooper Companies’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts anticipate that Cooper Companies will post 4.53 EPS for the current year.
Cooper Companies declared that its Board of Directors has initiated a stock buyback plan on Wednesday, September 9th that allows the company to buy back $3 billion in shares. This repurchase authorization allows the medical device company to reacquire up to 22.7% of its shares through open market purchases. Share repurchase plans are generally a sign that the company’s management believes its shares are undervalued.
About Cooper Companies
CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.
See Also
- Five stocks we like better than Cooper Companies
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.
